6 Ways to Elevate Your Machine Translation Strategy

Future-proof your MT strategy for clinical and regulatory content with this guide.

AI Driven

With 2025 well underway, innovators in the global life sciences and pharmaceutical industries continue to question how to maximize efficiencies and reduce complexities in clinical and regulatory content development and localization. As part of the broader technological roadmap, AI and automation remain front and center as key players in taking these workflows to new heights. Here are six approaches to ensure you don’t miss a pivotal step when adapting and applying your process.

translation_factory

1. Translation Model Customization

The pharmaceutical industry commands precision and optimal quality in all content. MT models should therefore be tailored and regularly updated such that they align with industry-specific terminology and have built-in glossaries that enforce accuracy and consistency across all translated materials. Using translation memories (TMs) and engine customization with company-specific data enables teams to repurpose pre-approved translations to cut down on review cycle times and ensure content uniformity when compared to “off-the-shelf” machine translation models.

Learn more about how machine translation drives success ›

2. Integration with Clinical & Regulatory Technologies

From a workflow perspective, MT can be integrated directly into additional content repositories, like an eTMF, RIM, web CMS, and more. This generates faster and more secure MT workflows that can be initiated from those same systems where your documents are authored and stored, in a secure “closed loop” ecosystem. In addition, integration with technologies like generative AI and natural language processing can yield more sophisticated language understanding and translation than MT alone. Explore 5 essential use cases for AI automation in regulatory content.

clinical_practice
contact

3. Increased Use of Multimodal Translation

With continually evolving capabilities and new use cases being identified, MT may extend beyond text to include multimodal elements, such as translating audio, images, graphs, and other visual content commonly found in pharmaceutical documents. This could enhance the overall translation of complex information and provide significant efficiencies in areas like patient recruitment and medical information, which more frequently utilize multi-channel and non-document-based content.

4. Enhanced Post-Editing Automation

Automation of post-editing processes has become more sophisticated, mitigating the need for extensive human intervention post-MT. Generative AI tools embedded within the review module leveraged by post-editors results in more streamlined workflows and rapid delivery of high-quality, fully reviewed translations.

post_editing
Forrester TEI GlobalLink for Life Sciences

5. Compliance Monitoring and Reporting

MT systems have evolved to incorporate multifaceted tools, such as built-in compliance monitoring features, ensuring that translations comply with specific regulatory requirements through automated checks for terminology consistency and language compliance, for example.

Key steps for regulatory submissions ›

6. Real-Time Collaboration Tools

The integration of real-time collaboration tools within MT platforms enhances efficiency and enables global teams to work simultaneously on translation projects. Features like live editing, instant feedback, and collaborative workflows help cut down the time needed to make documents submission-ready.

discussion regulatory

Additional Resources & Expert Perspectives

Buyer's Guide: Translation Management Integration with Veeva Vault RIM

Translation bottlenecks, fragmented audit trails, and uncontrolled AI output aren't edge cases in regulatory operations; they're the predictable result of a poorly integrated workflow. This buyer's guide is built for regulatory leaders who need more than a file-moving connector between their TMS and Veeva Vault RIM. Inside, you'll find a detailed evaluation framework, a vendor due diligence checklist, and a breakdown of the compliance, AI ...

Buyer's Guide: Translation Management Integration with Veeva Vault RIM
Blog

AI Governance in Medical Information: What "Human-in-the-Loop" Actually Requires

These days, you can't have a conversation about AI in life sciences without someone invoking "human-in-the-loop." It's become so expected that leaving it out feels like a red flag—a signal that AI governance hasn't been fully considered. The problem isn't the phrase...
Event

C3 Summit 2025 - London

Conversations on Clinical Content, C3 Summit is part of a series of events hosted by TransPerfect Life Sciences featuring sessions with expert panels discussing present challenges, strategies, and innovations, as well as insights into future advancements, from R&D to ...
White Paper

Libraries in Clinical Outcome Assessments: How Valuable Are They—and Are They the Panacea They’re Claimed to Be?

Speed, cost, and quality are competing priorities in eCOA localization. Discover why translation libraries alone aren't enough, and what combination of proactive licensing, automation, and integrated technology can transform your deployment timelines. ...
Blog

From Reactive to Strategic: How AI Is Transforming Medical Information Contact Centers

IntroductionFor decades, Medical Information (MI) has been an essential function within pharma, but largely a reactive one. This is especially true in medical information contact centers, which serve as the first line of support for HCPs and patients. When someone has a...
Blog

Is AI Ready to Transform COA Development?

AI is reshaping clinical development, but its greatest value may lie not in replacing human expertise, but rather in augmenting it. Across the drug development pipeline, AI is helping teams analyze vast datasets faster, identify promising compounds earlier, and uncover...
Blog

Five Domains the FDA Wants You to Measure in PROs for Cancer—and Why Translation Affects All of Them

In a recent "LifeSci Talks" episode, TransPerfect Global Practice Leader Mark Wade and Signant Health VP and eCOA Scientist Bill Byrom PhD discussed how new FDA guidance is reshaping how sponsors approach patient-reported outcomes (PROs) in cancer clinical trials. PROs...

Reach out to our team of AI and MT experts to get started today.

How did you hear about us?
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.